Free Trial
NASDAQ:NGNE

Neurogene Q2 2025 Earnings Report

Neurogene logo
$18.48 -0.36 (-1.91%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$18.47 -0.01 (-0.05%)
As of 08/29/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neurogene EPS Results

Actual EPS
-$1.05
Consensus EPS
-$1.15
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Neurogene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neurogene Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Neurogene's Q3 2025 earnings is scheduled for Monday, November 17, 2025, with a conference call scheduled on Tuesday, November 18, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Neurogene Earnings Headlines

Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.17
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome
One tiny company just cracked Google’s $19B problem
For decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. Then an MIT team cracked the code… dropping the cost from $63,000 to just 90 cents per gram. Now, one US-based factory is gearing up to supply the AI, aerospace, and EV industries with the one material they can’t continue to grow without. Only one company controls it, and its stock is still flying under Main Street’s radar.tc pixel
See More Neurogene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neurogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurogene and other key companies, straight to your email.

About Neurogene

Neurogene (NASDAQ:NGNE), a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

View Neurogene Profile

More Earnings Resources from MarketBeat